JOMED sets up subsidiary in Singapore:
This article was originally published in Clinica
JOMED is to set up a subsidiary in Singapore to sell its minimally-invasive vascular intervention products. The privately-owned Swedish company previously used an agent to sell its products. The new subsidiary will serve as a base for sales in other neighbouring markets such as Malaysia, Thailand, Indonesia and the Philippines, JOMED says. The company, which has manufacturing and R&D sites in Germany and Switzerland, also plans to float in Germany.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.